Document is current
Any future updates will be listed below
-
Authors
Knitza, Johannes http://orcid.org/0000-0001-9695-0657
Mohn, Jacob
Bergmann, Christina
Kampylafka, Eleni
Hagen, Melanie
Bohr, Daniela
Morf, Harriet
Araujo, Elizabeth
Englbrecht, Matthias
Simon, David
Kleyer, Arnd
Meinderink, Timo
Vorbrüggen, Wolfgang
von der Decken, Cay Benedikt
Kleinert, Stefan
Ramming, Andreas
Distler, Jörg H. W.
Vuillerme, Nicolas
Fricker, Achim
Bartz-Bazzanella, Peter
Schett, Georg
Hueber, Axel J.
Welcker, Martin
-
Funding
Funding for this research was provided by:
Novartis Pharma (33419272)
Universitätsklinikum Erlangen
- License Information
-
More Information
Article History
Received: 14 January 2021
Accepted: 31 March 2021
First Online: 13 April 2021
Declarations
:
: The study was approved by the ethics committee of the Medical Faculty of the University of Erlangen-Nürnberg, Germany (106_19 Bc), and reported to the German Clinical Trials Register (DRKS) (DRKS00017642).
: Not applicable.
: JK has received research support from Novartis Pharma GmbH. Qinum and RheumaDatenRhePort developed and hold rights for Rheport. WV, CD, SK, PB, and MW are members of RheumaDatenRhePort. AF, WV, CD, and PB were involved in the development of Rheport. JK is a member of the scientific board of RheumaDatenRhePort.
